Lumakras (sotorasib)

News alerts, weekly reports and conference planners

Company:

Amgen, BeiGene, Carmot Therapeutics

Drug class:

KRAS G12C inhibitor

Related drugs:

‹

›

KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	sotorasib Resistant: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Resistant : B ASCO 2023 - 1wk	sotorasib Resistant: B - Late Trials ASCO 2023 - 1 week sotorasib Resistant : B ASCO 2023 - 1 week - (New B)
KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Sensitive : B ASCO 2023 - 1wk	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week sotorasib Sensitive : B ASCO 2023 - 1 week - (New B)
KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Sensitive : B ASCO 2023 - 1wk	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week sotorasib Sensitive : B ASCO 2023 - 1 week - (New B)
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	sotorasib Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) sotorasib Sensitive : C1 ASCO 2023 - 1wk	sotorasib Sensitive: C1 - Off-label ASCO 2023 - 1 week sotorasib Sensitive : C1 ASCO 2023 - 1 week - (New C3)
STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) sotorasib Resistant : C3 ASCO 2023 - 1wk	sotorasib Resistant: C3 – Early Trials ASCO 2023 - 1 week sotorasib Resistant : C3 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 1 week (New D) sotorasib + OTS514 Sensitive : D J Cell Mol Med - 1wk	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 1 week sotorasib + OTS514 Sensitive : D J Cell Mol Med - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib + AbGn-107 Sensitive: C3 – Early Trials sotorasib + AbGn-107 Sensitive : C3	sotorasib + AbGn-107 Sensitive: C3 – Early Trials sotorasib + AbGn-107 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: C3 – Early Trials panitumumab + sotorasib Sensitive : C3	panitumumab + sotorasib Sensitive: C3 – Early Trials panitumumab + sotorasib Sensitive : C3
KRAS G12C + PD-L1 underexpression	Non Small Cell Lung Cancer	KRAS G12C + PD-L1 underexpression	Non Small Cell Lung Cancer	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C + PD-L1 underexpression + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + PD-L1 underexpression + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	pembrolizumab + sotorasib Sensitive: C3 – Early Trials pembrolizumab + sotorasib Sensitive : C3	pembrolizumab + sotorasib Sensitive: C3 – Early Trials pembrolizumab + sotorasib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	atezolizumab + sotorasib Sensitive: C3 – Early Trials atezolizumab + sotorasib Sensitive : C3	atezolizumab + sotorasib Sensitive: C3 – Early Trials atezolizumab + sotorasib Sensitive : C3
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + TPX-0005 Sensitive: D – Preclinical sotorasib + TPX-0005 Sensitive : D	sotorasib + TPX-0005 Sensitive: D – Preclinical sotorasib + TPX-0005 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	afatinib + sotorasib Sensitive: D – Preclinical afatinib + sotorasib Sensitive : D	afatinib + sotorasib Sensitive: D – Preclinical afatinib + sotorasib Sensitive : D
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	sotorasib + RMC-4550 Sensitive: D – Preclinical sotorasib + RMC-4550 Sensitive : D	sotorasib + RMC-4550 Sensitive: D – Preclinical sotorasib + RMC-4550 Sensitive : D
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	palbociclib + sotorasib Sensitive: D – Preclinical palbociclib + sotorasib Sensitive : D	palbociclib + sotorasib Sensitive: D – Preclinical palbociclib + sotorasib Sensitive : D
STK11 deletion + KRAS mutation	Non Small Cell Lung Cancer	STK11 deletion + KRAS mutation	Non Small Cell Lung Cancer	MEK inhibitor + sotorasib Sensitive: D – Preclinical MEK inhibitor + sotorasib Sensitive : D	MEK inhibitor + sotorasib Sensitive: D – Preclinical MEK inhibitor + sotorasib Sensitive : D

Lumakras (sotorasib)

Associations
(65)

Associations
(65)

Lumakras (sotorasib)

Associations(65)

Associations(65)

Associations
(65)

Associations
(65)